| Title |
Expanding the Boundaries of Biotherapeutics with Bispecific Antibodies
|
|---|---|
| Published in |
BioDrugs, August 2018
|
| DOI | 10.1007/s40259-018-0299-9 |
| Pubmed ID | |
| Authors |
Bushra Husain, Diego Ellerman |
| Abstract |
Bispecific antibodies have moved from being an academic curiosity with therapeutic promise to reality, with two molecules being currently commercialized (Hemlibra® and Blincyto®) and many more in clinical trials. The success of bispecific antibodies is mainly due to the continuously growing number of mechanisms of actions (MOA) they enable that are not accessible to monoclonal antibodies. One of the earliest MOA of bispecific antibodies and currently the one with the largest number of clinical trials is the redirecting of the cytotoxic activity of T-cells for oncology applications, now extending its use in infective diseases. The use of bispecific antibodies for crossing the blood-brain barrier is another important application because of its potential to advance the therapeutic options for neurological diseases. Another noteworthy application due to its growing trend is enabling a more tissue-specific delivery or activity of antibodies. The different molecular solutions to the initial hurdles that limited the development of bispecific antibodies have led to the current diverse set of bispecific or multispecific antibody formats that can be grouped into three main categories: IgG-like formats, antibody fragment-based formats, or appended IgG formats. The expanded applications of bispecific antibodies come at the price of additional challenges for clinical development. The rising complexity in their structure may increase the risk of immunogenicity and the multiple antigen specificity complicates the selection of relevant species for safety assessment. |
X Demographics
The data shown below were collected from the profiles of 13 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | 23% |
| Germany | 1 | 8% |
| Guinea-Bissau | 1 | 8% |
| Denmark | 1 | 8% |
| Unknown | 7 | 54% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 12 | 92% |
| Science communicators (journalists, bloggers, editors) | 1 | 8% |
Mendeley readers
The data shown below were compiled from readership statistics for 207 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 207 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 40 | 19% |
| Student > Ph. D. Student | 29 | 14% |
| Student > Bachelor | 26 | 13% |
| Other | 25 | 12% |
| Student > Doctoral Student | 10 | 5% |
| Other | 21 | 10% |
| Unknown | 56 | 27% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 60 | 29% |
| Agricultural and Biological Sciences | 21 | 10% |
| Immunology and Microbiology | 17 | 8% |
| Medicine and Dentistry | 11 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 10 | 5% |
| Other | 28 | 14% |
| Unknown | 60 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 20. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 April 2024.
All research outputs
#1,906,156
of 25,734,859 outputs
Outputs from BioDrugs
#40
of 756 outputs
Outputs of similar age
#38,170
of 343,150 outputs
Outputs of similar age from BioDrugs
#2
of 13 outputs
Altmetric has tracked 25,734,859 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 756 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.5. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 343,150 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 13 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 84% of its contemporaries.